粪菌移植治疗难治性肠易激综合征的效果观察  

Effect of fecal microbiota transplantation on refractory irritable bowel syndrome

作　　者：蔡萌豪 韩宇[1] 张彩凤[1] CAI Meng-hao;HAN Yu;ZHANG Cai-feng(Department of Gastroenterology,the First Affiliated Hospital of Xinxiang Medical College,Weihui,Henan 453100,China;不详)

机构地区：[1]新乡医学院第一附属医院消化内科,河南卫辉453100

出　　处：《中国微生态学杂志》2022年第4期440-444,共5页Chinese Journal of Microecology

基　　金：河南省科技攻关项目(192102310315)。

摘　　要：目的观察粪菌移植(FMT)对难治性肠易激综合征的治疗效果,为该病的治疗提供参考。方法招募我院32例难治性肠易激综合征患者并分为治疗组(n=17)和对照组(n=15),两组患者均给予马来酸曲美布汀片口服,治疗组进一步通过鼻肠管行FMT。分别于治疗1个月和3个月时评估两组患者临床疗效及安全性,并严格记录不良反应。结果治疗组患者FMT治疗前、治疗1个月和治疗3个月时IBS-SSS评分和粪便分型逐渐降低(均P<0.05),而对照组患者这3个时间点IBS-SSS评分和粪便分型差异无统计学意义(均P>0.05)。FMT治疗前两组患者IBS-SSS评分和粪便分型差异无统计学意义(均P>0.05)。治疗1个月和治疗3个月时,两组患者IBS-SSS评分差异均有统计学意义(均P<0.05)。治疗组患者FMT治疗前、治疗1个月和治疗3个月时IBS-QOL和HAD评分逐渐降低(均P<0.05),而对照组患者这3个时间点的IBS-QOL和HAD评分差异无统计学意义(均P>0.05)。FMT治疗前,两组患者IBS-QOL和HAD评分差异无统计学意义(均P>0.05)。治疗1个月时两组患者IBS-QOL评分差异有统计学意义(P<0.05),而HAD评分差异无统计学意义(P>0.05)。治疗3个月时两组患者IBS-QOL和HAD评分差异均有统计学意义(均P<0.05)。治疗组患者症状缓解率高于对照组(88.2%vs 53.3%)。治疗3个月后两组患者均未出现明显不良反应且未发现传染性疾病。结论FMT对难治性肠易激综合征有一定的临床疗效,且安全可靠。Objective To observe the therapeutic effect of fecal microbiota transplantation(FMT)on refractory irritable bowel syndrome(IBS),so as to provide reference for the treatment of the disease.Methods A total of 32 patients with refractory IBS in our hospital were enrolled and divided into the observation group(n=17)or control group(n=15).The patients in both groups were given oral Trimebutine Maleate tablets,and the observation group received additional FMT through nasointestinal tube.The clinical efficacy and safety were evaluated 1 month and 3 months after treatment respectively,and the adverse reactions were accurately recorded.Results The IBS-SSS score and stool type of patients in the observation group decreased gradually from 0 month,1 month to 3 months after treatment(all P<0.05);there were no significant differences in IBS-SSS score and stool type among the three time points in the control group(all P>0.05).Before FMT treatment,there were no differences in IBS-SSS score and stool type between the two groups(all P>0.05).There were significant differences in IBS-SSS scores between the two groups after 1 month and 3 months of treatment(all P<0.05).IBS-QOL and HAD scores in the observation group gradually decreased at 0,1 month and 3 months of FMT treatment(all P<0.05).In control group,there was no difference in IBS QOL and HAD scores at the 3 time points(all P<0.05).There were no differences in IBS-QOL and HAD scores between the two groups before FMT treatment(all P>0.05).After 1 month treatment,there was significant difference in IBS-QOL scores between the two groups,but no difference in HAD scores.After 3 months of treatment,there were significant differences in IBS-QOL and HAD scores between the two groups(all P<0.05).The efficacy in the observation group was higher than in control group(88.2%vs 53.3%).After three months of treatment,there were no obvious adverse reactions and no infectious transmitted diseases in both groups.Conclusion FMT is safe and reliable and has a certain clinical effect on refractory

关 键 词：粪菌移植 肠易激综合征 安全性 

分 类 号：R452[医药卫生—治疗学]